Prostate Cancer | Specialty

Research Initiative Comparing Proton Therapy With IMRT in Prostate Cancer

August 27th 2019

Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.

Armamentarium Continues to Evolve Across Metastatic Prostate Cancer

August 26th 2019

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Dr. Henderson on Proton Therapy Versus IMRT in Prostate Cancer

August 22nd 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

FDA Grants Enzalutamide Priority Review for Metastatic Hormone-Sensitive Prostate Cancer

August 21st 2019

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

August 20th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Dr. Henderson on the Benefits of Proton Therapy in Prostate Cancer

August 16th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.

Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy

August 15th 2019

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.

Dr. Tan on Imaging Modalities in Prostate Cancer

August 15th 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.

Dr. Jain on Novel Imaging Technologies for Prostate Cancer

August 13th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses new imaging modalities to detect disease in patients with prostate cancer.

Nonmetastatic CRPC Paradigm Bursting With Influx of AR Inhibitors

August 12th 2019

Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.

Vogelzang Highlights Decades of Innovation in Prostate Cancer

August 12th 2019

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses groundbreaking developments that have transformed the treatment of prostate cancer, as well as current issues in urology.

Where Sipuleucel-T Fits in the Treatment of mCRPC

August 9th 2019

Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.

Dr. George on Promise of PARP Inhibitors in Prostate Cancer

August 9th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.

Olaparib Improves Radiographic PFS in HRR-Mutant mCRPC

August 7th 2019

Olaparib demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared with enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who harbor a homologous recombination repair gene mutation and have progressed on prior therapy with either androgen receptor inhibitor, meeting the primary endpoint of the phase III PROfound trial.

ADT Associated With Alzheimer Disease, Dementia in Prostate Cancer Survivors

August 6th 2019

Androgen deprivation therapy (ADT) increases the risk of subsequent Alzheimer disease and dementia among men ≥66 years with prostate cancer, according to findings of a large retrospective study that examined the link between ADT treatment and later cognitive dysfunction.

Dr. Stadler on Active Surveillance in Prostate Cancer

August 1st 2019

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Role of PARP Inhibitors in Prostate Cancer

July 31st 2019

Considerations for Genetic Testing in Prostate Cancer

July 31st 2019

Sequencing in Nonmetastatic and Metastatic CRPC

July 31st 2019

Patient Selection for Radium-223 in mCRPC

July 31st 2019